Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Koriyama, Yoshiki ^a   Furukawa, Ayako ^a   Muramatsu, Michiru ^b   Takino, Jun Ichi ^c   Takeuchi, Masayoshi ^d  

^a SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; GLUCOSE; GLYCERALDEHYDE; TAU PROTEIN;

ALZHEIMER DISEASE; DRUG EFFECTS; GLYCOLYSIS; HUMAN; METABOLISM; NERVE CELL; NEUROBLASTOMA; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL LINE, TUMOR; GLUCOSE; GLYCERALDEHYDE; GLYCOLYSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NEUROBLASTOMA; NEURONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84940063315     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13313     Document Type: Article

References (44)

1. Takeuchi, M. et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr. Alzheimer Res. 1, 39-46 (2004).
2. Selkoe, D. J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 17, 489-517 (1994).
3. Takeuchi, M., Makita, Z. Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr. Mol. Med. 1, 305-315 (2001).
4. Takeuchi, M., Yamagishi, S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med. Hypotheses 63, 449-452 (2004).
5. Takeuchi, M., Takino, J., Yamagishi, S. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: A novel therapeutic strategy. Curr. Drug Targets 11, 1468-1482 (2010).
6. Sato, T. et al. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 21, 197-208 (2006).
7. Sasaki, N. et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 153, 1149-1155 (1998).
8. Takeuchi, M. et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59, 1094-1105 (2000).
9. Blennow, K., Hampel, H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605-613 (2003).
10. Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 1, 213-225 (2004).
11. Formichi, P. et al. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J. Cell Physiol. 208, 39-46 (2006).
12. Zhou, X. W. et al. Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. Neurobiol. Dis. 22, 657-668 (2006).
13. Tarkowski, E. et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol. Aging 23, 237-243 (2002).
14. Hunt, A. et al. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res. 155, 147-154 (2007).
15. Mosconi, L., Pupi, A., De Leon, M. J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N. Y. Acad. Sci. 1147, 180-195 (2008).
16. Lardy, H. A., Wiebelhaus, V. D., Mann, K. M. The mechanism by which glyceraldehyde inhibits glycolysis. J. Biol. Chem. 187, 325-337 (1950).
17. Needham, D. M., Siminovitch, L., Rapkine, S. M. On the mechanism of the inhibition of glycolysis by glyceraldehyde. Biochem. J. 49, 113-124 (1951).
18. Arvanitakis, Z. et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61, 661-666 (2004).
19. Ott, A. et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942 (1999).
20. Gasparini, L. et al. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol. Sci. 23, 288-293 (2002).
21. Watson, G. S., Craft, S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17, 27-45 (2003).
22. Peila, R., Rodriguez, B. L., Launer, L. J. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262 (2002).
23. Yan, S. D. et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691 (1996).
24. Smith, M. A. et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 91, 5710-5714 (1994).
25. Yan, S. D. et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med. 1, 693-699 (1995).
26. Vitek, M. P. et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 4766-4770 (1994).
27. Loske, C. et al. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J. Neural. Transm. 105, 1005-1015 (1998).
28. de Arriba, S. G. et al. Advanced glycation endproducts induce changes in glucose consumption, lactate production, and ATP levels in SH-SY5Y neuroblastoma cells by a redox-sensitive mechanism. J. Cereb. Blood Flow Metab. 23, 1307-1313 (2003)
29. Kuhla, B. et al. Differential effects of Advanced glycation endproducts and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J. Neural. Transm. 111, 427-439 (2004).
30. Takeuchi, M. et al. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5, 393-405 (1999).
31. Takeuchi, M. et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol. Med. 6, 114-125 (2000).
32. Choei, H. et al. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol. 108, 189-193 (2004).
33. Mazzola, J. L., Sirover, M. A. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J. Neurochem. 76, 442-449 (2001).
34. Mazzola, J. L., Sirover, M. A. Subcellular alteration of glyceraldehyde-3-phosphate dehydrogenase in Alzheimer's disease fibroblasts. J. Neurosci. Res. 71, 279-285 (2003).
35. Kang, J. H. et al. Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies. Korean J. Physiol. Pharmacol. 18, 447-456 (2014).
36. Zetterberg, H., Andreasen, N., Blennow, K. Increased cerebrospinal fluid levels of transforming growth factor-? 1 in Alzheimer's disease. Neurosci. Lett. 367, 194-196 (2004).
37. Shuvaev, V. V. et al. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 22, 397-402 (2001).
38. Chen, S. et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience 256, 137-146 (2014).
39. Takeuchi, M., Yamagishi, S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 14, 973-978 (2008).
40. Oates, P. J. Polyol pathway and diabetic peripheral neuropathy. Int. Rev. Neurobiol. 50, 325-392 (2002).
41. Hallfrisch, J. Metabolic effects of dietary fructose. FASEB J. 4, 2652-2660 (1990).
42. Hassel, B. Uptake and metabolism of fructose by rat neocortical cells in vivo and by isolated nerve terminals in vitro. J. Neurochem. 133, 572-581 (2015).
43. Bais, R. The purification and properties of human liver ketohexokinase. A role for ketohexokinase and fructose-bisphosphate aldolase in the metabolic production of oxalate from xylitol. Biochem. J. 230, 53-60 (1985).
44. Tahara, N. et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products (AGEs) and vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Diabetes Care 35, 2618-2625 (2012).